<DOC>
	<DOCNO>NCT00285194</DOCNO>
	<brief_summary>The collective effect two-layer pancreas preservation , pretransplant islet culture , day -2 pretransplant immunosuppression , induction immunosuppression FcR-nonbinding anti-CD3 monoclonal antibody hOKT3γ1 ( Ala-Ala ) facilitate diabetes reversal single-donor islet transplantation .</brief_summary>
	<brief_title>hOKT3γ1 ( Ala-Ala ) Combined With Sirolimus Delayed Tacrolimus Type 1 Diabetic Islet Allograft Recipients</brief_title>
	<detailed_description>This open-label , one-year follow-up study type 1 diabetic islet allograft recipient receive FcR non-binding OKT3 antibody hOKT3γ1 ( Ala-Ala ) plus sirolimus induction immunotherapy combine sirolimus delay tacrolimus maintenance immunosuppression . Six subject transplant . The premise behind proposal hOKT3γ1 ( Ala-Ala ) correct imbalance autoreactive regulatory T cell consequently prevents autoimmune destruction transplant islet . To prevent allorejection , hOKT3γ1 ( Ala-Ala ) combine sirolimus delay tacrolimus . Additionally , safety efficacy maintenance immunosuppressive regimen sirolimus combine tacrolimus monitor .</detailed_description>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Primary islet allotransplant 2 . Type 1 diabetes mellitus , complicate least one follow situation persist despite intensive effort close cooperation diabetes care team : 1 . Metabolic lability/instability ; 2 . Reduced awareness hypoglycemia ; 3 . Persistently poor glucose control ( define HgbA1c &gt; 10 % end six month intensive management effort diabetes care team ) ; 4 . Progressive secondary complication . 3 . Age 18 old 4 . Able give write informed consent 1 . Age le 18 year 2 . Body weight great than75 kg . 3 . BMI great 26 kg/m2 male female 4 . Waisttohip ratio 0.80 ( female ) 0.95 ( male ) 5 . First degree relative type 2 diabetes 6 . Insulin requirement great 0.7 IU/kg/day 7 . HbA1C great 12 % 8 . Positive Cpeptide response intravenous arginine stimulation 9 . Untreated proliferative retinopathy 10 . Macroalbuminuria ( urinary albumin excretion great 300 mg/24hrs ) 11 . Creatinine clearance great 85 ml/min/1.73 m2 female , great 95 ml/min/1.73 m2 males 12 . Serum creatinine great 1.2 mg/dl 13 . Previous pancreas islet transplant 14 . Previous OKT3 antibody therapy 15 . Presence history panelreactive antiHLA antibody great 10 % 16 . Abnormal T4 TSH despite thyroid replacement therapy 17 . Positive pregnancy test , presently breastfeed 18 . Active infection 19 . Negative screen EpsteinBarr Virus ( EBV ) EBNA method 20 . Invasive aspergillus infection within year prior study entry 21 . Any history malignancy 22 . Active alcohol substance abuse 23 . History nonadherence prescribe regimens 24 . Psychiatric disorder make subject suitable candidate transplantation 25 . Karnofsky performance score great 70 26 . Baseline Hgb great 11.7 g/dl ; lymphopenia ( great 1,000/L ) , leukopenia ( great 4,000 total leukocytes/L ) , absolute CD4+ count &lt; 500/L 27 . Thrombocytopenia great 150 x 109/L 28 . Use warfarin anticoagulant therapy ( except aspirin ) patient PTINR great 1.5 29 . Severe coexist cardiac disease 30 . Baseline liver function test outside normal range 31 . Presence gallstone baseline ultrasound exam 32 . Active peptic ulcer disease 33 . Severe unremitting diarrhea gastrointestinal disorder potentially interfere ability absorb oral medication 34 . Celiac disease 35 . Hyperlipidemia ( fast LDL cholesterol great 130 mg/dl , treat untreated ; and/or fasting triglyceride great 200 mg/dl ) 36 . Addison 's disease . 37 . Under treatment medical condition require chronic use systemic steroid 38 . Any medical condition , opinion investigator , interfere safe completion trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>